Pulse Biosciences (PLSE) Cash from Financing Activities (2017 - 2025)

Pulse Biosciences' Cash from Financing Activities history runs 9 years deep, the most recent figure standing at $381000.0 for Q4 2025.

• On a quarterly basis, Cash from Financing Activities fell 99.21% year-over-year to $381000.0 in Q4 2025; TTM through Dec 2025 was $17.2 million, a 84.43% decrease from a year earlier, with the FY2025 full-year figure at $17.2 million, down 84.43% from the prior year.
• Cash from Financing Activities slipped to $381000.0 in Q4 2025 per PLSE's latest filing, from $2.0 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $65.1 million in Q3 2022 and bottomed at -$549000.0 in Q4 2021.
• The 5-year median for Cash from Financing Activities is $2.1 million (2023), against an average of $15.1 million.
• Across the five-year window, Cash from Financing Activities jumped 19278.03% in 2021 and sank 564.62% in 2023, its largest moves.
• Year by year, Cash from Financing Activities stood at -$549000.0 in 2021, then jumped by 96.9% to -$17000.0 in 2022, then surged by 4829.41% to $804000.0 in 2023, then soared by 5895.27% to $48.2 million in 2024, then plunged by 99.21% to $381000.0 in 2025.
• Per Business Quant, the three latest PLSE Cash from Financing Activities figures stand at $381000.0 (Q4 2025), $2.0 million (Q3 2025), and $14.8 million (Q1 2025).